fluoxetine has been researched along with imiquimod in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J | 1 |
2 other study(ies) available for fluoxetine and imiquimod
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Depressive-like behaviors in mice with Imiquimod-induced psoriasis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain; Cytokines; Depression; Disease Models, Animal; Epinephrine; Exploratory Behavior; Fluoxetine; Food Preferences; gamma-Aminobutyric Acid; Imiquimod; Male; Mice, Inbred BALB C; Neurotransmitter Agents; Norepinephrine; Open Field Test; Psoriasis; Serotonin; Skin | 2020 |